Download presentation
Presentation is loading. Please wait.
1
Risk Factors for Migraine Chronification
2
Preventive Migraine Treatments Are Grossly Underutilized
3
Identifying Patients for Preventive Migraine Treatment Modified Criteria
4
Discontinuation and Switching With Oral Preventive Medications for Migraine
5
FDA-Approved CGRP-Targeted mAbs
6
Preventive Trials in Episodic Migraine Dropout Rates Due to AEs
7
mAbs Are Effective in Prior Treatment Failure
8
CGRP-Targeted mAb on QoL
9
Change in MMD in Patients With MOH Treated with Erenumab
10
Target, Route of Administration, Half-Life, and Tmax of CGRP mAbs for the Prevention of Migraine
11
Onset of Effect Is Rapid With CGRP-Targeted mAbs
12
Response to Galcanezumab Over First 3 Months of Treatment
13
3-Year Open-Label Erenumab and Cardio- and Cerebrovascular Event Rate
14
Abbreviations
15
Abbreviations
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.